Compare YDES & NMAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | YDES | NMAI |
|---|---|---|
| Founded | 2013 | 2021 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | | Investment Managers |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 543.0M | 458.6M |
| IPO Year | 2024 | N/A |
| Metric | YDES | NMAI |
|---|---|---|
| Price | $4.19 | $14.60 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 174.8K | 82.2K |
| Earning Date | 05-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 13.14% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.64 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $22.77 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.70 | $11.99 |
| 52 Week High | $25.00 | $15.06 |
| Indicator | YDES | NMAI |
|---|---|---|
| Relative Strength Index (RSI) | 57.16 | 53.82 |
| Support Level | $1.99 | $13.48 |
| Resistance Level | $5.15 | $15.06 |
| Average True Range (ATR) | 0.84 | 0.19 |
| MACD | -0.09 | -0.01 |
| Stochastic Oscillator | 49.21 | 64.17 |
YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.
Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund's investment objective is to provide total return through high current income and capital appreciation.